These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28648439)

  • 1. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
    Dalal JJ; Mishra S
    Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic treatment of stable coronary artery disease – the present and perspectives].
    Wsół A; Mamcarz A
    Przegl Lek; 2016; 73(6):395-8. PubMed ID: 29671300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.
    Ambrosio G; Tamargo J; Grant PJ
    Diab Vasc Dis Res; 2016 Mar; 13(2):98-112. PubMed ID: 26873904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metabolic approach in diabetic patients with coronary artery disease.
    Fragasso G; Salerno A; Spoladore R; Cera M; Montanaro C; Margonato A
    Curr Pharm Des; 2009; 15(8):857-62. PubMed ID: 19275650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic therapy for heart failure].
    Loiacono F; Alberti L; Lauretta L; Puccetti P; Silipigni C; Margonato A; Fragasso G
    Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
    O'Meara E; McMurray JJ
    Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
    Liu Z; Chen JM; Huang H; Kuznicki M; Zheng S; Sun W; Quan N; Wang L; Yang H; Guo HM; Li J; Zhuang J; Zhu P
    Metabolism; 2016 Mar; 65(3):122-30. PubMed ID: 26892523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
    Rosano GM; Vitale C; Fragasso G
    Am J Cardiol; 2006 Sep; 98(5A):14J-18J. PubMed ID: 16931201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New oral nitric oxide-dependent medications for patients with coronary artery disease who have persistent angina pectoris.
    Blum A
    Coron Artery Dis; 2015 Dec; 26(8):639-41. PubMed ID: 26528628
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic support for the heart: complementary therapy for heart failure?
    Heggermont WA; Papageorgiou AP; Heymans S; van Bilsen M
    Eur J Heart Fail; 2016 Dec; 18(12):1420-1429. PubMed ID: 27813339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.
    Rehberger-Likozar A; Šebeštjen M
    Coron Artery Dis; 2015 Dec; 26(8):651-6. PubMed ID: 26049922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina.
    César LA; Gowdak LH; Mansur AP
    Curr Pharm Des; 2009; 15(8):841-9. PubMed ID: 19275648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic treatment of coronary artery disease and heart failure.
    Di Napoli P
    Curr Pharm Des; 2009; 15(8):826. PubMed ID: 19275645
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS; Hill JA
    Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic therapy for the diabetic patients with ischaemic heart disease.
    Rosano GM; Vitale C; Volterrani M; Fini M
    Coron Artery Dis; 2005 Nov; 16 Suppl 1():S17-21. PubMed ID: 16340399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.
    Lopatin YM; Rosano GM; Fragasso G; Lopaschuk GD; Seferovic PM; Gowdak LH; Vinereanu D; Hamid MA; Jourdain P; Ponikowski P
    Int J Cardiol; 2016 Jan; 203():909-15. PubMed ID: 26618252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic modulation: a new therapeutic target in treatment of heart failure.
    Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
    Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic therapy of heart failure.
    Fragasso G; Salerno A; Spoladore R; Bassanelli G; Arioli F; Margonato A
    Curr Pharm Des; 2008; 14(25):2582-91. PubMed ID: 18991675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
    Lopaschuk GD
    Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.